Pre-Open Movers 4/16: POZEN (POZN) Surges On FDA Approval; Movado (MOV) Higher on Upgrade

April 16, 2008 9:21 AM EDT

StreetInsider.com Pre-Open Movers:

POZEN Inc. (Nasdaq: POZN) 44% HIGHER; GlaxoSmithKline (NYSE: GSK) and POZEN announced today that the FDA has approved Treximet for the acute treatment of migraine attacks with or without aura in adults. Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines pioneered by GSK, and an anti-inflammatory pain reliever in a single tablet

Source Interlink Companies, Inc. (Nasdaq: SORC) 36% HIGHER; reports Q EPS of $0.20, versus $0.18 last year. Revenues for the quarter rose 47.3% to $706.4 million, versus the consensus of $602.5 million.

CV Therapeutics, Inc. (Nasdaq: CVTX) 20% HIGHER; announced that TPG-Axon Capital has agreed to pay CV Therapeutics up to $185 million in exchange for rights to 50 percent of CV Therapeutics' royalty on North American sales of Lexiscan(TM) (regadenoson) injection.

Badger Meter (NYSE: BMI) 13.6% HIGHER; reports Q1 EPS of $0.41, 8 cents better than the analyst estimate of $0.33. Revenues for the quarter came in at $68.42 million, versus the consensus of $58.74 million.

Oscient Pharmaceuticals (Nasdaq: OSCI) 11.7% LOWER; expects to record total Q1 revenues of approximately $18.5 million, which is below the consensus of $27.9 million. The Company reiterates its previously announced guidance of $96-$103 million in revenues from ANTARA and FACTIVE tablets in 2008 and $28-$30 million in net cash utilization

Intel Corporation (Nasdaq: INTC) 7.4% HIGHER; reports Q1 EPS of $0.25, or $0.29 ex-items, 4 cents better than the analyst estimate of $0.25. Revenues for the quarter came in at $9.67 billion, versus the consensus of $9.63 billion Sees Q2 revs of $9-$9.6 billion, versus the consensus of $9.23 billion. Sees Q2 gross margin of 56 percent plus or minus a couple of points.

Movado Group Inc. (NYSE: MOV) 5.8% HIGHER; Morgan Joseph upgrades to Buy

JP Morgan Chase (NYSE: JPM) 2.9% HIGHER; reports Q1 earnings of $0.68 per share, 4 cents better than estimates. Revenues came in at $16.89 billion, versus the consensus of $16.97 billion

CSX Corporation (NYSE: CSX) 2.1% HIGHER; reports Q1 EPS of $0.85, with 5 cents in items, versus the analyst estimate of $0.74. Revenues for the quarter came in at $2.7 billion, versus the consensus of $2.63 billion. Reflecting the company's strong first quarter performance and the underlying strength of its business, CSX is now targeting the upper end of its previously announced 2008 EPS guidance of $3.40 - $3.60 on a comparable basis.

Linear Technology (Nasdaq: LLTC) 2% HIGHER; reports Q3 EPS of $0.44, 1 cent better than the analyst estimate of $0.43. Revenues for the quarter came in at $297.9 million, versus the consensus of $297.04 million.

Blackrock (NYSE: BLK) 2% LOWER; reports Q1 earnings $1.90 versus consensus of $2.00, missing by 10c. Blackrock reported Q1 revenue $1.3 billion versus consensus of $1.29 billion.

Coca-Cola (NYSE: KO) 1.7% HIGHER; reports Q1 EPS of $0.67, ex-items, 5 cents better than the analyst estimate of $0.62. Revenues for the quarter came in at $6.96 billion, excluding structural charges, verus the consensus of $6.85 billion.

Seagate (NYSE: STX) 1.6% LOWER; reports Q3 adj-EPS of $0.70, 1 cent better than the analyst estimate of $0.69. Revenues for the quarter came in at $3.1 billion, versus the consensus of $3.25 billion. The company expects to report revenue of $2.85 - $3.0 billion, and EPS ex-items of $0.41 - $0.45 The consensus is $3.11 billion and $0.57, respectively

WaMu (NYSE: WM) 1.2% HIGHER; announced a first quarter 2008 net loss of $1.14 billion, or $1.40 per diluted share (Consensus was loss of $1.05), compared with the fourth quarter net loss of $1.87 billion, or $2.19 per diluted share, and net income of $784 million, or $0.86 per diluted share, during the first quarter of 2007.

Get This Report E-Mailed To You Daily and Much, Much More With StreetInsider.com Premium - FREE TRIAL

Related Categories

Special Reports

Stocks Mentioned

Related Entities

• JPMorgan
• TPG-Axon Capital
• Morgan Joseph

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?